Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval

Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is at 88; compared to its 52-week range of 79 to 399.

You May Also Be Interested In

• Senate votes to halt Iran war unless Trump gets approval from Congress
• Qualcomm (QCOM) June 26 weekly 200 and 230 calls active into investor meeting
• Tenable Holdings, Inc. (TENB) call put ratio 80 calls to 1 put with a focus on 200 contracts of July 32 calls as share price up 5.6%